UNSPSC 51372702: Metethoheptazine

This classification denotes an opioid receptor agonist with the molecular formula C17H25NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier S36J5ZY2TH, chemically known as 1,3-dimethyl-4-carbethoxy-4-phenylhexamethylenimin but generally known as metethoheptazine, which bears US NIH Compound Identifier 176888. European Medicines Agency schedules Metethoheptazine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08829MIG. The term METETHOHEPTAZINE is an International Non-Proprietary Name.

UNSPSC 51372702 Metethoheptazine is a Commodity code under which state and local governments purchase pharmaceutical products, though recent solicitations tagged with this code reveal significant divergence from the nominal scope. The three most recent opportunities involve naloxone and drug deactivation systems (Seminole County, Florida), direct-to-manufacturer prescription program capabilities (Texas Health and Human Services Commission), and generic multi-source pharmaceuticals and over-the-counter products through cooperative purchasing (Minnesota Multistate Cooperative Purchasing Alliance). The issuing bodies span county health departments, state health and human services agencies, and multi-state cooperative purchasing alliances. Actual procurement under codes in this family reflects broader pharmaceutical supply and distribution activity rather than a single active pharmaceutical ingredient.

Activity is geographically dispersed across Florida, Texas, and Minnesota, with the Minnesota MMCAP cooperative extending to Oregon. Representative recent opportunities include Seminole County's IFB for 1,900 units of naloxone and 800 safe drug deactivation systems annually (posted June 30, 2026, due July 26, 2023), the Texas HHS Commission's RFI on direct-to-manufacturer prescription programs (posted April 3, 2026), and the Minnesota Department of Administration's RFP for generic multi-source pharmaceuticals and OTC products through authorized wholesalers (posted January 20, 2026, due March 26, 2026). The MMCAP procurement required compliance with current Good Manufacturing Practices and Drug Supply Chain Security Act standards, submission through ePro, pricing in multiple formats, and a 3 percent administrative fee on all contract purchases. No recent opportunities show explicit set-aside designations for disadvantaged enterprises.